Patients with dyskeratosis congenita (DC), a disorder of telomere maintenance, suffer degeneration of multiple tissues 1-3 . Patientspecific induced pluripotent stem (iPS) cells 4 represent invaluable in vitro models for human degenerative disorders like DC. A cardinal feature of iPS cells is acquisition of indefinite self-renewal capacity, which is accompanied by induction of the telomerase reverse transcriptase gene (TERT) [5] [6] [7] . We investigated whether defects in telomerase function would limit derivation and maintenance of iPS cells from patients with DC. Here we show that reprogrammed DC cells overcome a critical limitation in telomerase RNA component (TERC) levels to restore telomere maintenance and self-renewal. We discovered that TERC upregulation is a feature of the pluripotent state, that several telomerase components are targeted by pluripotencyassociated transcription factors, and that in autosomal dominant DC, transcriptional silencing accompanies a 39 deletion at the TERC locus. Our results demonstrate that reprogramming restores telomere elongation in DC cells despite genetic lesions affecting telomerase, and show that strategies to increase TERC expression may be therapeutically beneficial in DC patients.
Patients with dyskeratosis congenita (DC), a disorder of telomere maintenance, suffer degeneration of multiple tissues [1] [2] [3] . Patientspecific induced pluripotent stem (iPS) cells 4 represent invaluable in vitro models for human degenerative disorders like DC. A cardinal feature of iPS cells is acquisition of indefinite self-renewal capacity, which is accompanied by induction of the telomerase reverse transcriptase gene (TERT) [5] [6] [7] . We investigated whether defects in telomerase function would limit derivation and maintenance of iPS cells from patients with DC. Here we show that reprogrammed DC cells overcome a critical limitation in telomerase RNA component (TERC) levels to restore telomere maintenance and self-renewal. We discovered that TERC upregulation is a feature of the pluripotent state, that several telomerase components are targeted by pluripotencyassociated transcription factors, and that in autosomal dominant DC, transcriptional silencing accompanies a 39 deletion at the TERC locus. Our results demonstrate that reprogramming restores telomere elongation in DC cells despite genetic lesions affecting telomerase, and show that strategies to increase TERC expression may be therapeutically beneficial in DC patients.
Reprogramming of somatic cells to a state of pluripotency is characterized by prolonged self-renewal, implying induction of telomere maintenance mechanisms. Recently, it was reported that reprogramming of mouse cells was accompanied by elongation of telomeres 8 , but given the significant differences in telomere length and telomerase regulation in mouse and human cells, we asked whether normal human cells displayed telomere elongation after reprogramming. We generated iPS cell lines by retroviral transduction of primary human fibroblasts with the factors OCT4 (also known as POU5F1), SOX2, KLF4 and c-MYC (also known as MYC), confirmed the pluripotent phenotype by gene expression and functional analysis 4 , and determined the mean terminal restriction fragment (TRF) length of the donor fibroblast lines and corresponding iPS lines by Southern blot. We found that mean TRF length and total telomeric DNA was increased in iPS cell lines relative to the parental fibroblasts ( Supplementary Fig. 1a ). Similar findings using retrovirally-marked single-cell fibroblast sub-clones 5 contradict the notion that cells with long telomeres are uniquely susceptible to reprogramming ( Supplementary Fig. 1b ). Induction of TERT expression and telomerase activity correlated with reprogramming to pluripotency as shown previously [5] [6] [7] ( Supplementary Figs 1c-e ). These data establish that direct factor-based reprogramming of human somatic cells results in net telomere elongation. X-linked DC is caused by mutations in the dyskerin gene (DKC1) 9 which encodes an RNA binding protein whose inactivation destabilizes the levels of TERC, resulting in shortened telomeres and premature senescence in patient cell lines 10, 11 . We asked whether a DKC1 mutant fibroblast line (del37L, refs 9-11) could be reprogrammed and propagated in a pluripotent state. Compared to normal cells, the reprogramming efficiency of del37L cells was poor, yielding only 2-5 colonies from 10 5 input cells with a delayed latency ( Supplementary Table 1 ). Nevertheless, DKC1 mutant iPS colonies showed all the hallmarks of pluripotency, including characteristic morphology ( Fig. 1a ), gene expression ( Fig. 1b and Supplementary Fig. 2a ), and formation of teratomas comprising all three embryonic germ layers ( Fig. 1c ). PCR restriction fragment length polymorphism (RFLP) analysis for the DKC1 mutation confirmed the del37L mutation in iPS lines, and karyotype analysis was normal ( Fig. 1d and Supplementary Fig. 2b, c) . These data show that the somatic cells from patients with a genetic impairment in telomere elongation can be reprogrammed to pluripotency.
Despite induction of endogenous TERT and telomerase activity (Figs 1b, e), early passage del37L iPS cell lines displayed shorter telomeres relative to the starting fibroblast population ( Fig. 1f ). Addition of TERT to the reprogramming factors did not result in telomere elongation in del37L mutant cells ( Fig. 1f ), unlike in normal cells ( Supplementary Fig. 3 ), but did increase reprogramming efficiency (Supplementary Table 1 ; Supplementary Information). We obtained similar results with reprogramming of an independent DKC1 mutant line (A386T, ref. 11) ( Fig. 1g , Supplementary Fig. 4 and Supplementary Table 1 ). Given the telomerase dysfunction and shortened telomeres, we expected to observe limited passage of DKC1 mutant iPS cells in culture. However, unlike the parental DKC1 mutant fibroblasts, which senesced after 3-4 passages, we were able to continuously culture the DKC1 mutant iPS cell lines. Compared to the early passage cells, we found by TRF analysis that telomere length in del37L iPS lines increased with continued passage ( Fig. 2a ). Consistent with this, despite numerous interval population doublings, late passage del37L iPS lines had telomere lengths comparable to the original fibroblast population by quantitative PCR 12 (Fig. 2b) . In a blinded assessment by the complementary method of quantitative telomere fluorescence in situ hybridization, we confirmed that telomere length was shortened immediately after derivation but increased over time ( Fig. 2c ). Late passage del37L iPS cells maintained a characteristic morphology, normal karyotype, and the same clonal fingerprint as early passage cells, and reversion of the genetic mutation in DKC1 was excluded ( Supplementary Fig. 5 ). These data show that even in cells carrying genetic lesions that reduce telomerase function, reprogramming restores telomere elongation and self-renewal.
Previous studies have shown that reduced TERC levels compromise telomerase activity in DKC1 mutant fibroblasts 11 . Ectopic expression of TERT alone results in telomere elongation in wild-type fibroblasts 13, 14 , whereas expression of both TERC and TERT is required to restore telomere elongation in DKC1 mutant fibroblasts 11 (Supplementary Fig. 6 ). We therefore investigated TERC levels in DC fibroblasts and iPS cells. By quantitative RT-PCR, we found that TERC levels in DKC1 mutant fibroblasts were 10-15% of TERC levels found in wild-type fibroblasts, consistent with previous reports 10, 11 Fib  2  4  7  5  3  6  1 With TERT iPS
Telomerase activity assay Fig. 3a ). Relative to parental fibroblasts from two patients with different DKC1 mutations, we found TERC levels increased 6-8-fold in the reprogrammed derivatives, approaching levels in normal fibroblasts ( Fig. 3a) . In normal iPS cells, we found that TERC levels were approximately threefold higher than the fibroblasts from which they were derived ( Fig. 3a) . We next examined a cell line from a patient with autosomal dominant DC carrying a heterozygous 821 base pairs (bp) deletion in the 39 region of the TERC locus (DCHSF1, refs 15, 16) . In these TERC 1/2 fibroblasts TERC is limiting for telomere elongation, even in the presence of exogenous TERT 16 . We reprogrammed the TERC 1/2 patient fibroblasts and obtained several independent iPS lines that all showed characteristics of pluripotency and maintained the mutant genotype ( Supplementary Fig. 7 ). TERC 1/2 iPS cells also showed a threefold induction of TERC relative to fibroblasts (Fig. 3a) , and displayed continuous self-renewal in contrast to the early senescence seen in the parental fibroblasts 16 . These data demonstrate that reprogramming of somatic cells is accompanied by upregulation of endogenous TERC levels, and provide a mechanism for telomere elongation and indefinite self-renewal in DC iPS cell lines (Supplementary Fig. 6 ).
We found that human embryonic stem (ES) cells maintain elevated TERC levels similar to those found in wild-type iPS cells (Fig. 3a) , and that TERC levels attained in iPS cell lines derived from DKC1 mutant, TERC 1/2 and wild-type cells correlated with their respective telomerase activity (Fig. 3b ). Furthermore, TERC knockdown in DC iPS lines compromised telomere maintenance ( Supplementary Fig. 8a ). We found that the TERC locus is not amplified in DC iPS cells, and that on differentiation of DC iPS cells, TERC expression reverted to the pathologically low levels found in patient fibroblasts, and telomere length decreased ( Supplementary Fig. 8b-d) . Collectively, these results show that TERC levels are increased by reprogramming, and are a dynamically regulated and reversible property of the pluripotent state.
TERC abundance is tightly regulated by several transcriptional and post-transcriptional mechanisms 17, 18 . To investigate transcriptional mechanisms of TERC upregulation, we performed chromatin immunoprecipitation (ChIP) in human iPS cells, and detected enhanced binding of OCT4 and NANOG in the TERC locus (Fig. 3c) . These data were corroborated in murine ES cells, which likewise showed enhanced binding of OCT4 and NANOG at the TERC locus ( Supplementary Fig. 9 ). However, we were unable to detect increased levels of nascent TERC transcription by nuclear run-off assay in iPS cells versus fibroblasts ( Supplementary Fig. 10 ), indicating that OCT4 and NANOG may affect transcriptional competence rather than transcriptional rate of the TERC locus in pluripotent cells. Additional mechanisms are required to explain the increased steady-state levels of TERC. To investigate post-transcriptional mechanisms of TERC regulation, we determined DKC1 levels, which correlate with TERC levels in human cancer cells 19 . In all normal and DC iPS lines tested, we found an increase in DKC1 transcript levels and dyskerin protein relative to the fibroblasts (Figs 3d and e ). Moreover, we found that human ES cells, like iPS cells, maintain higher levels of DKC1 (Fig. 3d) , that DKC1 levels decreased with differentiation of iPS cells into embryoid bodies ( Supplementary  Fig. 11a ), and that DKC1 knockdown caused a reduction in TERC levels and compromised cellular viability ( Supplementary Fig. 11b, c) . ChIP showed binding of OCT4 and NANOG to the DKC1 promoter in pluripotent cells (Fig. 3f) , and infection of fibroblasts with retroviruses encoding the four reprogramming factors increased DKC1 levels ( Supplementary Fig. 11d ). These data establish that several telomerase components (TERT, TERC, DKC1) are upregulated after reprogramming, thereby accounting for increased telomerase activity in the pluripotent state and explaining the restoration of telomere maintenance in DC iPS cells.
In an autosomal dominant DC patient carrying an 821 bp deletion in the 39 region of TERC, earlier studies have concluded that the haploinsufficient phenotype is explained by impaired post-transcriptional accumulation of TERC RNA and reduced assembly of the truncated TERC RNA into telomerase holoenzyme [20] [21] [22] (Supplementary Fig. 12 ). Our ChIP data indicated OCT4 and NANOG binding in a region downstream of TERC that overlaps the 821 bp deletion (Fig. 3c) . Moreover, we found that part of this region is predicted to have regulatory potential on the basis of comparative genomic sequence alignment ( Supplementary Fig. 13a ). We proposed that loss of this region might compromise transcriptional activity of the deleted allele. We used two distinct allele-specific methods to analyse the chromatin configuration in TERC 1/2 iPS cells, and in both cases found the mutant TERC allele to be transcriptionally inactive (Fig. 4) . First, allele-specific ChIP showed a striking abrogation of H3K4me3 marks and RNA polymerase II binding on the deleted allele ( Fig. 4a and Supplementary Fig. 13b, c) . Second, allele-specific DNase I hypersensitivity analysis showed pronounced nuclease accessibility at the TERC promoter in normal cells (Fig. 4b ) and on the normal allele in TERC 1/2 cells, but complete loss of promoter hypersensitivity on the mutant TERC allele (Fig. 4c, d) . Collectively, these results identify a cis-element in the 39 region of the TERC locus that seems essential for formation of a transcriptionally active chromatin structure, and indicate that mutations in this region can cause haplo-insufficiency in autosomal dominant DC by diminishing TERC transcription (Supplementary Fig. 12 ). By reprogramming somatic cells from patients with the human disease dyskeratosis congenita, we have discovered novel mechanisms of regulation of telomerase activity in the pluripotent state, thus illustrating the value of disease-specific iPS cells for basic and translational discovery. Moreover, we have shown that the RNA component of telomerase is upregulated in the pluripotent state to a degree sufficient to overcome limitations to telomere maintenance in X-linked and autosomal dominant DC. Drugs that activate the TERC locus may favour telomere maintenance over premature attrition in stem cell compartments where TERT is present but telomerase activity is limiting, such as haematopoietic stem cells [23] [24] [25] [26] [27] , and thus might serve as therapeutic agents for bone marrow failure. Moreover, we speculate that in DC patients certain cell types such as germ cells and cancer cells, whose transcriptional programs share similarities with pluripotent cells, may also upregulate TERC to permit germline propagation of mutations and malignant proliferation.
METHODS SUMMARY
Fibroblast lines included GM01774 (DKC1 del37L) 11 , AG04646 (DKC1 A386T) 11 , DCHSF1 (TERC 1/2 821 bp deletion) 16 and NHSF2 (wild type) 16 . The derivation, characterization, culture and differentiation of iPS cells was performed as described 5 . Verification of mutations in GM01774 was as described 9 . Telomere length analysis was performed with the TeloTAGGG Telomere Length Assay kit (Roche). iPS cells were cultured feeder-free on Matrigel (Becton Dickinson) for telomerase and telomere quantitative real-time PCR (qPCR) assays. Telomere qFISH and qPCR were performed as described 12, 28 . Telomerase activity assays were performed using the TeloTAGGG Telomerase PCR ELISA and PCR ELISA PLUS kits (Roche). Detection of TERT, OCT4, SOX2, NANOG, and b-actin transcripts by RT-PCR was as described 5 . TERC and DKC1 transcript levels were measured using qPCR with quantification normalized to GAPDH. Primer sequences are provided in Methods. Chromatin immunoprecipitation was performed on BJ1, HFib2, NHSF2, and DCHSF1 iPS cells as described 29 . Antibodies and primers sequences are provided in Methods. Western blot was performed on total cellular lysates using antibodies against human dyskerin and actin (Santa Cruz). DNase I hypersensitivity analysis was performed as described 30 . Primer sequences for probes are provided in Methods.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. cultures were harvested as single cells using Accutase (Stem Cell Technologies), and 5 3 10 4 cells per well were plated in a 6-well plate on Matrigel (Becton Dickinson) in mTESR medium (Stem Cell Technologies) in the presence of 10 mM Y-27632 (Sigma) 37 . After 24 h viral supernatants were added in various quantities in the presence of 10 mg ml 21 protamine sulphate in mTESR medium for 6 h. After 48 h, infected cells were selected in 0.15 mg ml 21 puromycin and maintained thereafter in mTESR medium with Matrigel or in conventional hES medium on DR4 puromycin-resistant feeder cells. TERC copy number determination. TERC locus copy number in iPS relative to parental fibroblasts was determined by performing qPCR on genomic DNA from DCHSF1 (TERC 1/2 ) and del37L DKC1 mutant fibroblasts and their iPS derivatives. Primers for the TERC locus were TRC3F and TRC3R 35 and for the b-actin locus were ActinF (59-AACGGCAGAAGAGAGAACCAGTGA-39) and ActinR (59-TTCTACAATGAGCTGCGTGTGGCT-39). Amplification of the TERC locus was normalized to that of the b-actin locus for each sample, and results are displayed as a ratio of normalized TERC signal for iPS cells relative to the parent fibroblast. Error bars denote standard error from two biological replicates. Nuclear runoff transcription assay. Nuclei from 5 3 10 7 to 1 3 10 8 wild-type (NHSF2) fibroblasts or derivative iPS cells (NHSF2 iPS clone 1) were isolated and 32 P-labelled runoff transcripts were generated as described 38 . Labelled nascent RNA transcripts were purified using TRIzol (Invitrogen) and hybridization was performed using 1-2 3 10 6 c.p.m. ml 21 . Membranes containing hybridization targets were prepared by slot-blot of 5 mg linearized plasmid DNA targets containing full-length human TERC cloned into pUC19, a 439 bp fragment consisting of exon 3 of human b-actin cloned into pUC19, or pUC19 vector alone. Hybridization was performed using Rapid-Hyb buffer (G.E. Healthcare) with pre-hybridization for 12-16 h followed by hybridization for 48 h.
